scPharmaceuticals Inc. (SCPH)

NASDAQ: SCPH · IEX Real-Time Price · USD
4.140
+0.080 (1.97%)
Jun 14, 2024, 4:00 PM EDT - Market closed
1.97%
Market Cap 149.27M
Revenue (ttm) 17.63M
Net Income (ttm) -57.71M
Shares Out 36.05M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 113,197
Open 4.020
Previous Close 4.060
Day's Range 3.980 - 4.190
52-Week Range 3.240 - 11.050
Beta 0.07
Analysts Strong Buy
Price Target 19.00 (+358.94%)
Earnings Date Aug 8, 2024

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROS... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2017
Employees 135
Stock Exchange NASDAQ
Ticker Symbol SCPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SCPH stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 358.94% from the latest price.

Price Target
$19.0
(358.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...

16 days ago - GlobeNewsWire

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack

4 weeks ago - GlobeNewsWire

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...

4 weeks ago - GlobeNewsWire

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...

5 weeks ago - GlobeNewsWire

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2...

7 weeks ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023

3 months ago - GlobeNewsWire

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to opti...

3 months ago - GlobeNewsWire

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

3 months ago - GlobeNewsWire

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million

5 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednes...

7 months ago - GlobeNewsWire

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

8 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing pr...

9 months ago - GlobeNewsWire

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients

9 months ago - GlobeNewsWire

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to opti...

10 months ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today, Thurs...

11 months ago - GlobeNewsWire

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

11 months ago - GlobeNewsWire

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulation...

11 months ago - GlobeNewsWire

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

1 year ago - GlobeNewsWire

scPharmaceuticals to Present at the Jefferies Healthcare Conference

BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...

1 year ago - GlobeNewsWire

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Announced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116....

1 year ago - GlobeNewsWire

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi...

1 year ago - GlobeNewsWire

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic he...

1 year ago - GlobeNewsWire

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

Management to host conference call and webcast at 4:30 p.m. ET

1 year ago - GlobeNewsWire

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

1 year ago - GlobeNewsWire

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

BURLINGTON, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim...

1 year ago - GlobeNewsWire